Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy

Hematological malignancies are important diseases that need more powerful therapeutics. Even with current targeting therapies, such as rituximab and other chemotherapeutic agents, there is a need to develop new treatment strategies. Combination therapy seems the best option to target the tumor cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Shammari, Ahmed Majeed, Rameez, Huda, Al-Taee, Maha F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996254/
https://www.ncbi.nlm.nih.gov/pubmed/27579294
http://dx.doi.org/10.2147/OV.S95250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996254/
https://www.ncbi.nlm.nih.gov/pubmed/27579294
http://dx.doi.org/10.2147/OV.S95250

Ejemplares similares